The APS Phenotyping Study

Last updated: August 26, 2024
Sponsor: Vanderbilt University Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pneumonia

Soft Tissue Infections

Treatment

Surveys

CNS Vital Signs

Muscle Ultrasound

Clinical Study ID

NCT06521502
240088
  • Ages > 18
  • All Genders

Study Summary

The goal of the observational APS phenotyping study is to better understand risk factors, potential biomarkers, length and severity of illness, and recovery for adults with ARDS, pneumonia, and/ or sepsis. This study will also generate a biobank of specimens collected from these patients that will be available to investigators for future studies of ARDS, sepsis, and/or pneumonia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

To be eligible for enrollment, a patient must meet all the following inclusion criteria at the time of the first study-specified biospecimen collection (Time 0):

  1. Age ≥ 18 years old

  2. Admitted (or planned to be admitted) to an intensive care unit (ICU) or otherin-patient hospital location where IV vasopressors or advanced respiratory support (invasive mechanical ventilation, non-invasive ventilation, or high flow nasalcannula) are routinely provided (referred to as an "eligible unit.")

  3. Acute cardiovascular or pulmonary organ dysfunction defined by meeting at least oneof the two criteria below:

  • New receipt of invasive mechanical ventilation, non-invasive ventilation, highflow nasal cannula, or supplemental oxygen at a flow rate of ≥ 6 lpm for acutehypoxemia.a. Patients who use chronic oxygen therapy are eligible to participate if theyare receiving at least 6 lpm higher than their baseline oxygen requirement (e.g., a patient on 3 lpm O2 at baseline is eligible if they require ≥9 lpm forhypoxemia) or are started on advanced respiratory support (invasive mechanicalventilation, non- invasive ventilation, or high flow nasal cannula).

  • Receipt of intravenous infusion of a vasopressor medication for at least onehour.

  1. Acute cardiovascular or pulmonary organ dysfunction (inclusion criterion #3) isattributed to an acute inflammatory condition, including but not limited to any ofthe following:
  • Any infection including pneumonia.

  • Aspiration pneumonitis.

  • Pancreatitis.

  • Auto-inflammatory condition such as:

  1. Hemophagocytic lymphohistiocytosis.
  2. Suspected acute rheumatologic or auto-immune disease with pulmonary orcardiovascular manifestations.
  3. Suspected cryptogenic organizing pneumonia presenting acutely.
  4. Suspected diffuse alveolar hemorrhage.
  5. Suspected acute anaphylaxis.
  6. Suspected acute pulmonary drug toxicity.

Exclusion

Exclusion Criteria:

To be eligible for enrollment, a patient must not meet any of the following exclusion criteria at the time of the first study-specified biospecimen collection (Time 0):

  1. Patient/legally authorized representative (LAR) declines participation.

  2. Acute cardiovascular or pulmonary organ dysfunction (inclusion criterion #3) hasbeen present for > 48 hours.

  3. Patient has been in an eligible unit (inclusion criterion #2) for more than 120hours (five days).

  4. Patient is no longer expected to meet the acute cardiovascular or pulmonary organdysfunction inclusion criterion (inclusion criterion #3) 24 hours after enrollment.

  5. Patient desires comfort measures only.

  6. Patient is a prisoner.

  7. Patient had out-of-hospital cardiac arrest leading to this hospitalization.

  8. Residence immediately before this hospitalization in a long-term acute carefacility.

  9. Presence of tracheostomy for respiratory failure.

  10. Home invasive mechanical ventilation or non-invasive ventilation (except patientswith non-invasive ventilation prescribed as a treatment for a sleep disorder mayparticipate).

  11. Suspected cause of the patient's acute cardiovascular and/or pulmonary dysfunction (inclusion criterion #3) is an alternative condition (not ARDS, pneumonia, orsepsis), including but not limited to the list below:

  • Drug overdose (without aspiration, lung injury, pneumonia, or infection).

  • Trauma (without aspiration, pneumonia, or infection).

  • Chronic lung disease without suspected infection, aspiration, or inflammation.

  • Asthma, chronic obstructive pulmonary disease (COPD), sarcoidosis, interstitiallung disease, neuromuscular respiratory failure.

  • Status epilepticus.

  • Acute pulmonary embolism.

  • Acute decompensated heart failure.

  • Diabetic ketoacidosis.

  • Acute stroke or intracranial hemorrhage.

  • Acute bleeding (GI bleeding, post-procedural bleeding, hemolysis).

  • Cytokine release syndrome due to chemotherapy.

  1. Inability or unwillingness to complete study-specified blood draws, for example, dueto local policies about hemoglobin thresholds for research blood draws.

Study Design

Total Participants: 4000
Treatment Group(s): 16
Primary Treatment: Surveys
Phase:
Study Start date:
July 25, 2024
Estimated Completion Date:
April 30, 2028

Study Description

The APS phenotyping study will enroll hospitalized adult patients ≥18 years old who have or are at risk of developing ARDS, sepsis, or pneumonia. Participation in this study will involve collection of clinical data, completing questionnaires, and collection of samples such as blood, urine, and stool. Participants who are mechanically ventilated will also provide samples from their respiratory track. Data and samples will be collected both during and after hospitalization. Analyses to understand the mechanisms underlying ARDS, pneumonia, and sepsis will be conducted, with goals including the classification of patients with ARDS, pneumonia, and sepsis into biologically based phenotype categories and identifying new targets for future therapeutic trials.

Connect with a study center

  • Fresno Community Hospital and Medical Center

    Fresno, California 93721
    United States

    Site Not Available

  • Stanford University

    Palo Alto, California 94305
    United States

    Site Not Available

  • San Francisco General Hospital

    San Francisco, California 94110
    United States

    Site Not Available

  • University of California, San Francisco

    San Francisco, California 94143
    United States

    Site Not Available

  • Denver Health and Hospital Authority

    Denver, Colorado 80204
    United States

    Site Not Available

  • National Jewish Health

    Denver, Colorado 80206
    United States

    Site Not Available

  • University of Colorado, Denver

    Denver, Colorado 80045
    United States

    Active - Recruiting

  • University of Chicago

    Chicago, Illinois 60637
    United States

    Site Not Available

  • Johns Hopkins Univeristy

    Baltimore, Maryland 21218
    United States

    Site Not Available

  • University of Michigan

    Ann Arbor, Michigan 48109
    United States

    Site Not Available

  • Henry Ford Health System

    Detroit, Michigan 48202
    United States

    Site Not Available

  • Washington University School of Medicine

    Saint Louis, Missouri 63110
    United States

    Site Not Available

  • Duke University

    Durham, North Carolina 27710
    United States

    Site Not Available

  • University of Cincinnati

    Cincinnati, Ohio 45219
    United States

    Site Not Available

  • University of Pennsylvania

    Philadelphia, Pennsylvania 19104
    United States

    Site Not Available

  • Meharry Medical College

    Nashville, Tennessee 37208
    United States

    Site Not Available

  • Vanderbilt University Medical Center

    Nashville, Tennessee 37232
    United States

    Active - Recruiting

  • Intermountain Medical Center

    Murray, Utah 84107
    United States

    Active - Recruiting

  • University of Utah

    Salt Lake City, Utah 84132
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.